Furthermore, DNMT3B activity has a pivotal role in IL-6-mediated octamer-binding transcription factor 4 (OCT4) expression in sorafenib-resistant hepatocellular carcinoma (HCC), highlighting DNMT3B as a putative therapeutic target for patients expressing cancer stemness properties or sorafenib resistance in HCC [94]. This evidence concerns the gene IL6 and cancer.